LumiraDx (NASDAQ:LMDX) stock is taking off on Monday with a new partnership with AstraZeneca (NASDAQ:AZN) behind its rally.
This collaboration has LumiraDx working together with AstraZeneca and Everton in the Community to set up the first community-based heart and lung screening hub in England. These companies are expecting the facility to open in November.
Everton in the Community will handle the operations of the new screening facility. This is the official charity of the Everton Football Club. The goal of the location is to offer support to individuals suffering from chronic breathlessness and other issues from heart and lung conditions.
David Walton, Chief Commercial Officer at LumiraDx, said this about the news:
“A full blood draw can be daunting for patients, so the use of a simple fingerstick sample for our NT-proBNP test greatly broadens access to heart health checks within the community. By diagnosing heart failure faster, we aim to make a positive impact on patient outcomes, which then translates into positive economic outcomes for the NHS.”
LMDX Stock Movement on Monday
Shares of LMDX stock are rising higher alongside heavy trading on Monday. During pre-market hours, more than 35 million shares of the company’s stock have changed hands. That’s a massive increase in trading volume compared to its daily average of only about 272,000 shares.
LMDX stock is up 322.5% as of Monday morning.
Investors looking for more of the most recent stock market news are in the right place!
InvestorPlace offers all of the hottest stock market stories that traders need to know about on Monday! That includes the biggest pre-market stock movers this morning, the latest news concerning electric vehicle (EV) stocks and more. All of that news is ready to go down below!
More Monday Stock Market News
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
- EV Stocks Alert: China Just Issued a Key Blow to U.S. EV Makers
- Dear QS Stock Fans, Mark Your Calendars for Oct. 25
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
